Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia

Authors

Miguel Ruiz,¹ Zachary Braunstein,¹ Eric McLaughlin,² Anjali Mishra,³ Pierluigi Porcu³ and Jonathan E. Brammer⁴

¹Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH; ²Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH; ³Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology and Department of Cancer Biology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA and ⁴Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

Correspondence:

JONATHAN E BRAMMER - Jonathan.brammer@osumc.edu

https://doi.org/10.3324/haematol.2024.286235

Received: 20 July 2024.

Accepted: November 8, 2024.

Early view: November 14, 2024.

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license

Supplementary Table 1: Response by neutropenia and anemia status, Campath dosing, and STAT3/5 mutation

Variable	Group	Response rate (%)	Fisher p-value
All patients	All	6/8 (75%)	-
Neutropenia status	Not neutropenic	3/3 (100%)	0.57
	Neutropenia	1/1 (100%)	
	Severe neutropenia	2/4 (50%)	
Anemia status	No anemia	2/2 (100%)	1.0
	Anemia	4/6 (67%)	
Weeks of Campath	3-4	3/4 (75%)	1.0
	5-8	3/4 (75%)	
Doses of Campath	8-14	3/5 (60%)	0.46
	23-24	3/3 (100%)	
Campath line of treatment	1 st -3 rd	3/3 (100%)	0.46
	4 th -5 th	3/5 (60%)	
STAT3/STAT5 mutation	Negative	3/3 (100%)	0.25
	Positive	1/3 (33%)	
	Unknown	2/2 (100%)	

Supplemental Figure 1: Hemoglobin and Neutrophil Trends After scAlemtuzumab

